Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    October 2024
  1. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
    When is prostate cancer really cancer?
    J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
    PubMed     Abstract available


    September 2024
  2. EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al
    Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.
    J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093.
    PubMed     Abstract available


    August 2024
  3. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available


    July 2024
  4. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
    Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
    J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
    PubMed     Abstract available


    June 2024
  5. DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al
    Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
    J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093.
    PubMed     Abstract available


    May 2024
  6. BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al
    Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor Antagonists.
    J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  7. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
    PubMed    


  8. LAO Y, Guan X, Wang J, Bai Y, et al
    RE: Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study.
    J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093.
    PubMed    


    January 2024
  9. LEE KM, Nelson T, Bryant A, Teerlink C, et al
    Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
    J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
    PubMed     Abstract available


  10. WILKINSON S, Sowalsky AG
    Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
    J Natl Cancer Inst. 2024;116:12-14.
    PubMed    


  11. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2024;116:167-169.
    PubMed     Abstract available


    December 2023
  12. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
    J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093.
    PubMed     Abstract available


    November 2023
  13. FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al
    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
    J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093.
    PubMed     Abstract available


  14. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    PubMed    


    October 2023
  15. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    PubMed     Abstract available


  16. MA T, Jin L, Bai S, Liu Z, et al
    Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression.
    J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  17. KENSLER KH, Johnson R, Morley F, Albrair M, et al
    Prostate Cancer Screening in African American Men: A Review of the Evidence.
    J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093.
    PubMed     Abstract available


  18. SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al
    Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
    J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093.
    PubMed     Abstract available


    August 2023
  19. DANIELS JP, Freedland SJ, Gresham G
    The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    J Natl Cancer Inst. 2023 Aug 16:djad140. doi: 10.1093.
    PubMed    


  20. WOLINSKY H
    Re: Putting patients first to redefine prostate cancer classifications: Patients' viewpoints on redefining Grade Group 1.
    J Natl Cancer Inst. 2023 Aug 16:djad160. doi: 10.1093.
    PubMed    


    July 2023
  21. YOO M, Nelson RE, Haaland B, Dougherty M, et al
    Cost-Effectiveness Analysis of seven treatments In Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public-Payer Perspective.
    J Natl Cancer Inst. 2023 Jul 12:djad135. doi: 10.1093.
    PubMed     Abstract available


  22. NYAME YA, Gore JL, Lin DW
    Putting patients first to redefine prostate cancer classifications.
    J Natl Cancer Inst. 2023 Jul 10:djad124. doi: 10.1093.
    PubMed    


    June 2023
  23. HURWITZ LM, Dogbe N, Hughes Barry K, Koutros S, et al
    Obesity and prostate cancer screening, incidence, and mortality in the PLCO Cancer Screening Trial.
    J Natl Cancer Inst. 2023 Jun 29:djad113. doi: 10.1093.
    PubMed     Abstract available


  24. LUYENDIJK M, Visser O, Blommestein HM, de Hingh IHJT, et al
    Changes in survival in de novo metastatic cancer in an era of new medicines.
    J Natl Cancer Inst. 2023;115:628-635.
    PubMed     Abstract available


  25. BERLIN A, Ramotar M, Santiago AT, Liu Z, et al
    The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer.
    J Natl Cancer Inst. 2023 Jun 7:djad108. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  26. CHU CE, Leapman MS, Zhao S, Cowan JE, et al
    Prostate cancer disparities among American Indians/Alaskan Natives in the United States.
    J Natl Cancer Inst. 2023 Jan 11:djad002. doi: 10.1093.
    PubMed     Abstract available


  27. HAIMAN CA, Kote-Jarai Z, Darst BF, Conti DV, et al
    RE: Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2023 Jan 11:djad005. doi: 10.1093.
    PubMed    


  28. HOULAHAN KE, Livingstone J, Fox NS, Kurganovs N, et al
    A polygenic two-hit hypothesis for prostate cancer.
    J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  29. HU X, Lipscomb J, Jiang C, Graetz I, et al
    Vertical integration of oncologists and cancer outcomes and costs in metastatic Castration-Resistant prostate cancer.
    J Natl Cancer Inst. 2022 Dec 30:djac233. doi: 10.1093.
    PubMed     Abstract available


    November 2022

  30. Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
    J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
    PubMed    


    October 2022
  31. PAGADALA MS, Lynch J, Karunamuni R, Alba PR, et al
    Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
    J Natl Cancer Inst. 2022 Oct 28. pii: 6777270. doi: 10.1093.
    PubMed     Abstract available


  32. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
    Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
    J Natl Cancer Inst. 2022;114:1392-1399.
    PubMed     Abstract available


    September 2022
  33. AWASTHI S, Grass GD, Torres-Roca J, Johnstone PAS, et al
    Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
    J Natl Cancer Inst. 2022 Sep 2. pii: 6687132. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  34. TAKAHASHI T
    RE: Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Jul 26. pii: 6650145. doi: 10.1093.
    PubMed    


    June 2022
  35. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available


    April 2022
  36. LAI LY, Oerline MK, Caram MEV, Tsao PA, et al
    Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568024. doi: 10.1093.
    PubMed     Abstract available


  37. KEATING NL
    Cardiovascular and Metabolic Diagnoses Associated with Novel Hormonal Agents for Prostate Cancer in Non-Trial Populations.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568021. doi: 10.1093.
    PubMed    


  38. QIAO EM, Lynch JA, Lee KM, Kotha NV, et al
    Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    J Natl Cancer Inst. 2022;114:592-599.
    PubMed     Abstract available


    March 2022
  39. BORREGALES LD, DeMeo G, Gu X, Cheng E, et al
    Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Mar 28. pii: 6555003. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  40. MARK M, von Moos R, Cathomas R, Stoffel S, et al
    RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Nov 29. pii: 6446038. doi: 10.1093.
    PubMed    


    October 2021
  41. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  42. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available


  43. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    PubMed     Abstract available


  44. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  45. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    


  46. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available


  47. OLSSON H, Nordstrom T, Jaderling F, Egevad L, et al
    Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    J Natl Cancer Inst. 2021;113:632-640.
    PubMed     Abstract available


  48. BECKER DJ, Rude T, Walter D, Wang C, et al
    The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    J Natl Cancer Inst. 2021;113:626-631.
    PubMed     Abstract available


    April 2021
  49. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available


  50. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  51. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    


    October 2020
  52. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    


    September 2020
  53. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.